Intravenous Regional Analgesia of Dexmedetomidine

Study acronym: Dexmedetomidin
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 30, 2026 → Jun 30, 2027
See other at-risk trials from Mansoura University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 30, 2026 to Jun 30, 2027
    • Trial status changed: Enrolling by Invitation → Active, Not Recruiting
    • Eligibility criteria expanded, about 18 words
  2. Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Enrollment target: 50 to 100
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 30, 2025 to Jan 12, 2026
    • Eligibility criteria revised
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Dexmedetomidine is a highly selective α₂-adrenergic receptor agonist that exerts its effects by inhibiting the release of norepinephrine at presynaptic nerve terminals, leading to reduced sympathetic activity; This mechanism results in analgesia, sedation, and anxiolysis without significant respiratory depression
Trial Details
NCT Number NCT07131579
Lead Sponsor Mansoura University
Conditions
(from sponsor)		 Dexmedetomidine Analgesia, Knee Surgery
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov